검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Immune Checkpoint Inhibitors (Immune Checkpoint Inhibitors) Compugen Ltd·Hepatocellular Carcinoma ORR 59% |
|---|---|
Overview Program | Immune Checkpoint Inhibitors |
Overview Company | Compugen Ltd |
Overview Modality | ANTIBODY |
Overview Target | Hepatocellular Carcinoma |
Overview Indication | Biliary Tract Cancer; Immune Checkpoint Inhibitor |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | target of rapamycin (mTOR) pathway |
MoA Biomarker | biomarkers |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | Pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | De-escalation of Treatment in Metastatic Renal Cell Carcinoma: Why? How? Who? When?. The therapeutic landscape of metastatic renal cell carcinoma (mRCC) has evolved considerably with the introduction of immune checkpoint inhibitors (ICIs) and VEGFR-targeted therapies, leading to unprecedented improvements in survival. As durable responses and deep remissions become more frequent, the question of h… |
Toxicology CRS | Reported |
Clinical Primary efficacy | ORR 59% |
Clinical ORR | 59% |
Clinical Result source | ClinicalTrials.gov NCT03729245 |
Clinical Data Tier / Score | A · 55 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 12일 (2일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Immune Checkpoint Inhibitors (Immune Checkpoint Inhibitors) Compugen Ltd·Hepatocellular Carcinoma ORR 59% |
|---|---|
Overview Program | Immune Checkpoint Inhibitors |
Overview Company | Compugen Ltd |
Overview Modality | ANTIBODY |
Overview Target | Hepatocellular Carcinoma |
Overview Indication | Biliary Tract Cancer; Immune Checkpoint Inhibitor |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | target of rapamycin (mTOR) pathway |
MoA Biomarker | biomarkers |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | Pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | De-escalation of Treatment in Metastatic Renal Cell Carcinoma: Why? How? Who? When?. The therapeutic landscape of metastatic renal cell carcinoma (mRCC) has evolved considerably with the introduction of immune checkpoint inhibitors (ICIs) and VEGFR-targeted therapies, leading to unprecedented improvements in survival. As durable responses and deep remissions become more frequent, the question of h… |
Toxicology CRS | Reported |
Clinical Primary efficacy | ORR 59% |
Clinical ORR | 59% |
Clinical Result source | ClinicalTrials.gov NCT03729245 |
Clinical Data Tier / Score | A · 55 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 12일 (2일 전) |
추천 비교
추천 비교